Sanofi India Limited has announced a key change in its senior management team with the resignation of Mr. Suresh Babu, who served as Sales & Customer Engagement Head – Diabetes. The pharmaceutical company disclosed this development in compliance with regulatory requirements on February 12, 2026.

Resignation Details

Mr. Suresh Babu tendered his resignation from the services of the company effective from the close of business on February 12, 2026. The resignation was submitted to pursue other opportunities outside Sanofi, marking the end of his tenure as a Senior Management Personnel of the company.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made to both BSE Limited and The National Stock Exchange of India Limited, ensuring transparency with stakeholders and regulatory authorities.

Transition Process

According to the resignation correspondence, Mr. Babu initially proposed February 28 as his last working day to allow for proper handover and transition. However, the final arrangement resulted in his departure on February 12, 2026, after completing the necessary handover procedures. The departing executive expressed commitment to ensuring a smooth transition with all details for business continuity.

Corporate Documentation

The disclosure was signed by Haresh Vala, Company Secretary and Compliance Officer, and includes comprehensive documentation as required under SEBI regulations. The company has also uploaded this information on its official website for stakeholder access and transparency.

Sanofi India Limited has disclosed receiving a significant tax demand order from the Principal/Joint Commissioner of CGST & Central Excise, Mumbai. The pharmaceutical company made this disclosure on December 30, 2025, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Tax Demand Details

The order issued by the tax authorities covers a substantial period and involves significant financial implications for the company:

Nature of Alleged Violation

The tax demand order has been issued on account of alleged wrong availment and utilization of Input Tax Credit (ITC). This relates to the company's tax credit claims during the specified five-year period from FY 2018-19 to FY 2022-23.

Financial Impact

The total financial exposure includes:

• Primary tax demand: ₹1.43 crores
• Penalty amount: ₹1.43 crores (equal to the tax demand)
• Interest charges: To be calculated at applicable rates under CGST and IGST Act, 2017

The combined exposure of tax demand and penalty alone amounts to ₹2.87 crores, excluding the interest component which will be calculated separately.

Regulatory Compliance

Sanofi India Limited has fulfilled its disclosure obligations under SEBI regulations by promptly informing the stock exchanges. The disclosure was signed by Haresh Vala, Company Secretary and Compliance Officer (Membership No.: A18246), ensuring proper corporate governance protocols were followed.

The company submitted this information to both BSE Limited (Scrip Code: 500674) and National Stock Exchange of India Limited (Symbol: SANOFI) as required under the listing regulations.